Who is sponsoring NCT02612168?

NCT02612168 is sponsored by Skin Analytics Limited.

What drugs are being tested in NCT02612168?

Interventions in NCT02612168: Melanoma Image Analysis Algorithm (MIAA).

What condition does NCT02612168 study?

NCT02612168 studies Malignant Melanoma.

Is NCT02612168 still recruiting?

NCT02612168 is currently completed. Last updated 25 January 2019.

Last reviewed 2019-01-25 · How we verify

NCT02612168

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Melanoma Image Analysis Algorithm (MIAA) Validation Study

Completed NA Last updated 25 January 2019

What this trial tests

NA trial testing Melanoma Image Analysis Algorithm (MIAA) in Malignant Melanoma in 514 participants. Completed in 11 July 2018.

Timeline

11 January 2017

Primary endpoint
11 July 2018

11 July 2018

Quick facts

Lead sponsor	Skin Analytics Limited
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	514
Start date	11 January 2017
Primary completion	11 July 2018
Estimated completion	11 July 2018
Sites	7 locations across United Kingdom

Drugs / interventions tested

Melanoma Image Analysis Algorithm (MIAA)

Conditions studied

Malignant Melanoma — all drugs for Malignant Melanoma →

Sponsor

Skin Analytics Limited

Who can join

18 and older, any sex, with Malignant Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, single-arm, cross-sectional, study to establish the effectiveness of MIAA to detect melanoma in pigmented lesions, compared to gold standard histological determination.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Malignant Melanoma

Currently open trials in the same condition.

NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06961006 — A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0 · Phase 2 · recruiting
NCT06974734 — A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies · Phase 1 · active not recruiting
NCT06980740 — Video-Tumorboard PLUS · recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting

Other Skin Analytics Limited trials

Trials by the same sponsor.

NCT06654999 — How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions. · completed
NCT05126173 — DERM US and EU Validation Study · completed
NCT04116983 — DERM NMSC Validation Study · completed
NCT04123678 — DERM Health Economics Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02612168 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Skin Analytics Limited
Last refreshed: 25 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02612168.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing